BioGaia (OM:BIOG B) Q3 Earnings Justify A Premium Stock Valuation

BioGaia came into the Q3 2026 print with its stock at SEK129.3 and a strong three month run behind it. Expectations were primed for another clean beat from the probiotics specialist. The headline did not disappoint on profitability. Earnings per share reached SEK1.09 for the quarter while EBIT margin landed at 33% on SEK400.4m of sales. That margin performance, not the top line, is the real story. The share price move now reflects a simple test for investors. Belief in the premium P/E hinges on this type of profit delivery holding up.

Love BioGaia's 33% EBIT margin but concerned about paying up for a premium P/E without similar profitability elsewhere in your portfolio? Screen for companies that pair strong earnings quality with balance sheet strength using our list of solid balance sheet and fundamentals stocks (204 results).

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs Q3 2025): SEK400.4m vs. SEK326.6m (up about 23%)
• Net Income (Q3 2026 vs Q3 2025): SEK110.2m vs. SEK65.9m (up about 67%)
• Basic EPS (Q3 2026 vs Q3 2025): SEK1.09 vs. SEK0.65 (up about 67%)
• EBIT Margin (Q3 2026 vs Q3 2025): 33% vs. 26% (margin stepped up by around 7 percentage points)

Earnings tell you what BioGaia reported this quarter, but cash flows help you judge what you are really paying for those results over time. Looking at BioGaia's cash generation alone, the stock could be a notable 24% undervalued.

BioGaia bulls test the diversification and DTC thesis

BioGaia supporters argue that broader categories and more direct sales will turn today’s execution into tomorrow’s earnings power.

"BioGaia's strategic shift to direct sales in new and existing markets (e.g., Netherlands, France, Australia, U.S.) leverages rising consumer demand for natural and clinically-proven solutions, paving the way for improved operating leverage and long-term margin expansion as direct business now represents 36% of sales and continues to grow."

Q3 shows real progress against that plan. Direct markets helped lift Adult Health sales and supported a 73% gross margin. EBIT margin at 33% came in close to the long run 34% ambition despite ongoing marketing and R&D spend. This suggests the operating model is starting to scale rather than being purely volume driven.

BioGaia bear case on costs and dependence under review

Critics worry that high spending and a heavy pediatric skew will choke flexibility just as the product set broadens.

"High operating expenses, weak cash flow, and dependence on pediatric products pose profitability and diversification risks, potentially undermining long-term growth and financial flexibility."

The latest figures push back on the profitability part of that concern. EBIT rose faster than revenue and the 33% margin sits above last year’s 26%. Operating costs grew, yet management limited OpEx to low double digit growth while still funding new launches in skincare and colon health. Pediatrics remain large, but Adult Health grew 29% in Q3 and now contributes a bigger share, which slightly reduces category concentration.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Quiet Profit Engines

BioGaia just showed how a tight operating model can shift the earnings debate. The real opportunity sits in finding stocks that could be undervalued before that kind of reset happens.

• Company 1 - 49% below our estimate - expands an integrated chain of mines and smelters to lift zinc and copper output from existing brownfield and new greenfield projects.
• Company 2 - 34% below our estimate - converts record program wins in tightly regulated sectors into higher value manufacturing, once customers move complex designs from qualification into full production.
• Company 3 - 44% below our estimate - grows its concession portfolio by adding new airports and integrating recently acquired operations so more non-aeronautical projects feed into fee-based income.

Those are three of them. See the full list of 193 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com